Wen Chuan Zhou
Algemeen Directeur bij MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED
Vermogen: 592 131 $ op 30-04-2024
Actieve functies van Wen Chuan Zhou
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Directeur/Bestuurslid | 01-01-2009 | - |
| Algemeen Directeur | 01-01-2009 | - | |
| GONGNIU GROUP CO.,LTD. | Directeur/Bestuurslid | 20-05-2021 | - |
Shenzhen Wingor Bio-technology Co., Ltd.
 Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Directeur/Bestuurslid | - | - |
Loopbaan van Wen Chuan Zhou
Opleiding van Wen Chuan Zhou
| University of British Columbia | Graduate Degree |
| The Chinese University of Hong Kong | Masters Business Admin |
Statistieken
Internationaal
| Hongkong | 3 |
| China | 3 |
| Canada | 2 |
Operationeel
| Director/Board Member | 3 |
| Chief Executive Officer | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Consumer Services | 3 |
| Distribution Services | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED | Distribution Services |
| GONGNIU GROUP CO.,LTD. | Producer Manufacturing |
| Bedrijven in privébezit | 1 |
|---|---|
Shenzhen Wingor Bio-technology Co., Ltd.
Shenzhen Wingor Bio-technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shenzhen Wingor Bio-technology Co., Ltd. engages in the research and development, and production of anti-tumor biological immune cell products. It offers chimeric antigen receptor T lymphocyte, clustered regulatory interspaced short palindromic repeat, mesenchymal stem cell, methyl triazeno imidazole carboxamide technology, and cryobiomedical technology. The company was founded on March 12, 2013 and is headquartered in Shenzhen, China. | Commercial Services |
- Beurs
- Insiders
- Wen Chuan Zhou
- Ervaring
